Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.00.

ACRS has been the subject of several research reports. StockNews.com raised shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, July 25th. HC Wainwright reissued a "neutral" rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS traded up $0.09 during trading on Wednesday, hitting $1.80. 735,971 shares of the company's stock were exchanged, compared to its average volume of 995,201. The business's 50-day simple moving average is $1.21 and its 200 day simple moving average is $1.21. The company has a market cap of $128.28 million, a price-to-earnings ratio of -1.57 and a beta of 0.20. Aclaris Therapeutics has a 52-week low of $0.59 and a 52-week high of $5.71.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%. The firm had revenue of $2.77 million for the quarter, compared to analysts' expectations of $1.74 million. On average, sell-side analysts anticipate that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics during the 1st quarter worth approximately $39,000. BNP Paribas Financial Markets boosted its stake in shares of Aclaris Therapeutics by 10.9% during the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company's stock valued at $299,000 after purchasing an additional 23,747 shares during the period. Deuterium Capital Management LLC bought a new position in shares of Aclaris Therapeutics in the first quarter worth about $99,000. Marquette Asset Management LLC purchased a new position in Aclaris Therapeutics in the 1st quarter worth about $104,000. Finally, SG Americas Securities LLC lifted its holdings in Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company's stock valued at $41,000 after buying an additional 13,461 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.